265 related articles for article (PubMed ID: 18206427)
21. Genome-Wide CRISPR Screens Reveal ZATT as a Synthetic Lethal Target of TOP2-Poison Etoposide That Can Act in a TDP2-Independent Pathway.
Park JM; Zhang H; Nie L; Wang C; Huang M; Feng X; Tang M; Chen Z; Xiong Y; Lee N; Li S; Yin L; Hart T; Chen J
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047518
[TBL] [Abstract][Full Text] [Related]
22. Mre11 Is Essential for the Removal of Lethal Topoisomerase 2 Covalent Cleavage Complexes.
Hoa NN; Shimizu T; Zhou ZW; Wang ZQ; Deshpande RA; Paull TT; Akter S; Tsuda M; Furuta R; Tsutsui K; Takeda S; Sasanuma H
Mol Cell; 2016 Nov; 64(3):580-592. PubMed ID: 27814490
[TBL] [Abstract][Full Text] [Related]
23. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
24. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.
Nitiss KC; Malik M; He X; White SW; Nitiss JL
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):8953-8. PubMed ID: 16751265
[TBL] [Abstract][Full Text] [Related]
25. MDM2 provides TOP2 poison resistance by promoting proteolysis of TOP2βcc in a p53-independent manner.
Shu J; Jiang J; Wang X; Yang X; Zhao G; Cai T
Cell Death Dis; 2024 Jan; 15(1):83. PubMed ID: 38263255
[TBL] [Abstract][Full Text] [Related]
26. Myeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer Chemotherapy.
Atwal M; Lishman EL; Austin CA; Cowell IG
Mol Pharmacol; 2017 Jan; 91(1):49-57. PubMed ID: 27974636
[TBL] [Abstract][Full Text] [Related]
27. Topoisomerase II-Induced Chromosome Breakage and Translocation Is Determined by Chromosome Architecture and Transcriptional Activity.
Canela A; Maman Y; Huang SN; Wutz G; Tang W; Zagnoli-Vieira G; Callen E; Wong N; Day A; Peters JM; Caldecott KW; Pommier Y; Nussenzweig A
Mol Cell; 2019 Jul; 75(2):252-266.e8. PubMed ID: 31202577
[TBL] [Abstract][Full Text] [Related]
28. The topoisomerase IIbeta circular clamp arrests transcription and signals a 26S proteasome pathway.
Xiao H; Mao Y; Desai SD; Zhou N; Ting CY; Hwang J; Liu LF
Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3239-44. PubMed ID: 12629207
[TBL] [Abstract][Full Text] [Related]
29. NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.
Toyoda E; Kagaya S; Cowell IG; Kurosawa A; Kamoshita K; Nishikawa K; Iiizumi S; Koyama H; Austin CA; Adachi N
J Biol Chem; 2008 Aug; 283(35):23711-20. PubMed ID: 18596031
[TBL] [Abstract][Full Text] [Related]
30. NPRL-Z-1, as a new topoisomerase II poison, induces cell apoptosis and ROS generation in human renal carcinoma cells.
Wu SY; Pan SL; Xiao ZY; Hsu JL; Chen MC; Lee KH; Teng CM
PLoS One; 2014; 9(11):e112220. PubMed ID: 25372714
[TBL] [Abstract][Full Text] [Related]
31. MRN, CtIP, and BRCA1 mediate repair of topoisomerase II-DNA adducts.
Aparicio T; Baer R; Gottesman M; Gautier J
J Cell Biol; 2016 Feb; 212(4):399-408. PubMed ID: 26880199
[TBL] [Abstract][Full Text] [Related]
32. The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Xiao H; Goodrich DW
Oncogene; 2005 Dec; 24(55):8105-13. PubMed ID: 16091739
[TBL] [Abstract][Full Text] [Related]
33. Small Molecule Inhibitors Confirm Ubiquitin-Dependent Removal of TOP2-DNA Covalent Complexes.
Swan RL; Poh LLK; Cowell IG; Austin CA
Mol Pharmacol; 2020 Sep; 98(3):222-233. PubMed ID: 32587095
[TBL] [Abstract][Full Text] [Related]
34. Action of SN 28049, a new DNA binding topoisomerase II-directed antitumour drug: comparison with doxorubicin and etoposide.
Drummond CJ; Finlay GJ; Broome L; Marshall ES; Richardson E; Baguley BC
Invest New Drugs; 2011 Oct; 29(5):1102-10. PubMed ID: 20567995
[TBL] [Abstract][Full Text] [Related]
35. Sodium salicylate acts through direct inhibition of phosphoinositide 3-kinase-like kinases to modulate topoisomerase-mediated DNA damage responses.
Fan JR; Huang TH; Wen CY; Shen TL; Li TK
Eur J Pharmacol; 2010 Jul; 638(1-3):13-20. PubMed ID: 20406630
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase IIalpha-dependent induction of a persistent DNA damage response in response to transient etoposide exposure.
Soubeyrand S; Pope L; Haché RJ
Mol Oncol; 2010 Feb; 4(1):38-51. PubMed ID: 19858003
[TBL] [Abstract][Full Text] [Related]
37. Differential impact of diverse anticancer chemotherapeutics on the Cdc25A-degradation checkpoint pathway.
Agner J; Falck J; Lukas J; Bartek J
Exp Cell Res; 2005 Jan; 302(2):162-9. PubMed ID: 15561098
[TBL] [Abstract][Full Text] [Related]
38. Nemo-like kinase is critical for p53 stabilization and function in response to DNA damage.
Zhang HH; Li SZ; Zhang ZY; Hu XM; Hou PN; Gao L; Du RL; Zhang XD
Cell Death Differ; 2014 Oct; 21(10):1656-63. PubMed ID: 24926618
[TBL] [Abstract][Full Text] [Related]
39. Comparison of checkpoint responses triggered by DNA polymerase inhibition versus DNA damaging agents.
Liu JS; Kuo SR; Melendy T
Mutat Res; 2003 Nov; 532(1-2):215-26. PubMed ID: 14643438
[TBL] [Abstract][Full Text] [Related]
40. Signaling crosstalk of FHIT, CHK2 and p38 in etoposide induced growth inhibition in MCF-7 cells.
Mir Mohammadrezaei F; Mohseni kouchesfehani H; Montazeri H; Gharghabi M; Ostad SN; Ghahremani MH
Cell Signal; 2013 Jan; 25(1):126-32. PubMed ID: 23000346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
